Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.62 |
| ▸ | HPGD | P15428 | 3/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.62 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.56 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
| ▸ | MMP2 | P08253 | 3/20 | 0.55 |
| ▸ | MMP9 | P14780 | 3/20 | 0.55 |
| ▸ | MMP8 | P22894 | 3/20 | 0.55 |
| ▸ | MMP12 | P39900 | 3/20 | 0.55 |
| ▸ | MMP14 | P50281 | 3/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12031270 | 0.96 | SMN1; SMN2 (0.60) | SMN1; SMN2HPGDL3MBTL1HDAC1HDAC8 | |
| SCHEMBL7166265 | 0.91 | ALDH1A1 (0.59) | SMN1; SMN2HPGDL3MBTL1HDAC1LMNA | |
| SCHEMBL4086405 | 0.88 | HDAC1 (0.58) | SMN1; SMN2HPGDL3MBTL1HDAC1HDAC8 | |
| SCHEMBL10031688 | 0.87 | SMN1; SMN2 (0.54) | SMN1; SMN2HPGDL3MBTL1HDAC1HDAC8 | |
| SCHEMBL312780 | 0.85 | MMP2 (0.49) | SMN1; SMN2HPGDL3MBTL1HDAC1HDAC8 | |
| Fenbufen Butanamine SCHEMBL313629 | 0.84 | SMN1; SMN2 (0.54) | SMN1; SMN2HPGDL3MBTL1HDAC1HDAC8 | |
| SCHEMBL15522836 | 0.82 | THRA (0.51) | SMN1; SMN2HPGDL3MBTL1LMNAMMP2 | |
| SCHEMBL8496423 | 0.82 | ALDH1A1 (0.63) | SMN1; SMN2HPGDL3MBTL1HDAC1LMNA | |
| SCHEMBL6606979 | 0.81 | L3MBTL1 (0.79) | SMN1; SMN2HPGDL3MBTL1HDAC1HDAC8 | |
| SCHEMBL6360275 | 0.80 | DRD2 (0.78) | SMN1; SMN2L3MBTL1HDAC1HDAC8HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093427-B2 | Construction and screening of solution-phase derived library of fenbufen and ethacrynic acid | NATIONAL TSING HUA UNIVERSITY (TW) | 2012-01-10 | — | — | US | disclosed |
| US-8093427-B2 | Construction and screening of solution-phase derived library of fenbufen and ethacrynic acid | NATIONAL TSING HUA UNIVERSITY (TW) | 2012-01-10 | — | — | US | disclosed |
| US-20110306668-A1 | CONSTRUCTION AND SCREENING OF SOLUTION-PHASE DERIVED LIBRARY OF FENBUFEN AND ETHACRYNIC ACID | NATIONAL TSING HUA UNIVERSITY (TW) | 2011-12-15 | — | — | US | disclosed |
| US-20110306668-A1 | CONSTRUCTION AND SCREENING OF SOLUTION-PHASE DERIVED LIBRARY OF FENBUFEN AND ETHACRYNIC ACID | NATIONAL TSING HUA UNIVERSITY (TW) | 2011-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306668-A1 | CONSTRUCTION AND SCREENING OF SOLUTION-PHASE DERIVED LIBRARY OF FENBUFEN AND ETHACRYNIC ACID | CYP4F2, ACR, CYP4F3 | SMN1; SMN2 2503/4885HPGD 1294/4885L3MBTL1 1012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.